<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02690051</url>
  </required_header>
  <id_info>
    <org_study_id>FMRP-140702</org_study_id>
    <nct_id>NCT02690051</nct_id>
  </id_info>
  <brief_title>BeSmooth Study, Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions</brief_title>
  <acronym>BeSmooth</acronym>
  <official_title>BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flanders Medical Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flanders Medical Research Program</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Physician initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the
      treatment of Iliac Lesions.

      The objective of this clinical investigation is to evaluate the long-term safety and efficacy
      of the BeSmooth Peripheral Stent System in clinical settings post CE-certification when used
      according to the indications of the IFU.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Patency at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>defined as a target lesion without a hemodynamically significant stenosis on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.4) and without Target Lesion Revascularization (TLR) within 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency at 1 &amp; 6 month</measure>
    <time_frame>1 and 6 months</time_frame>
    <description>Patients that present without a hemodynamically significant stenosis at the target area on duplex ultrasound (&gt;50%, systolic velocity ratio no greater than 2.4) and without prior TLR are defined as being primary patent at the given follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Occlusion Rate at 1,6 and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>100% (re)occlusion rate within the study stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ABI at 1,6 and 12-month follow-up, compared with baseline</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Ankle-Brachial index measurements at 1,6 and 12-month FU visit, compared with measurements at baseline (pre operatively)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 1,6 and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance success rate at baseline, defined as restoration of blood flow</measure>
    <time_frame>during the index study procedure</time_frame>
    <description>Device success, restoration of blood flow during index procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent restenosis rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>restenosis rate within the study stent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Target Lesion Revascularization</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Freedom from Target Lesion Revascularization (TLR), defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Serious Adverse Events (SAEs), defined according to ISO 14155:2011 as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success</measure>
    <time_frame>during the index study procedure</time_frame>
    <description>The ability to achieve final residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success at follow-up is defined as an improvement of Rutherford Classification at 1-,6- and 12-month follow-up</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Clinical success at follow-up is defined as an improvement of Rutherford classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>BeSmooth Peripheral Stent system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with the BeSmooth Peripheral Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BeSmooth peripheral stent</intervention_name>
    <description>patients treated with the BeSmooth Peripheral Stent System</description>
    <arm_group_label>BeSmooth Peripheral Stent system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Corresponding to the CE-mark indications/contra-indications and according to the
             current medical guidelines for minimally invasive peripheral interventions.

          2. Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable
             for stenting (on indication for primary stenting, based on the discretion of the
             investigator)

          3. Patient presenting a score from 2 to 5 following Rutherford classification

          4. Patient is willing to comply with specified follow-up evaluations at the specified
             times for the duration of the study

          5. Patient is &gt;18 years old

          6. Patient (or their legal representative) understands the nature of the procedure and
             provides written informed consent, prior to enrolment in the study

          7. Patient is eligible for treatment with the BeGraft Peripheral Stent Graft System
             (Bentley InnoMed)

          8. The target lesion is either a modified TASC-II class A, B, C or D lesion with one of
             the listed specifications:

               -  Type A lesions

                    -  Unilateral or bilateral stenoses of the Common Iliac Artery

                    -  Unilateral or bilateral single short (≤3 cm) stenosis of the External Iliac
                       Artery

               -  Type B lesions

                    -  Unilateral Common Iliac Artery occlusion

                    -  Single or multiple stenosis totaling 3-10 cm involving the External Iliac
                       Artery not extending into the Common Femoral Artery

                    -  Unilateral External Iliac Artery occlusion not involving the origins of
                       Internal Iliac Artery or Common Iliac Artery

               -  Type C lesions

                    -  Bilateral Common Iliac Artery occlusions

                    -  Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the
                       Common Femoral Artery

          9. The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or
             occlusion which can be passed with standard guidewire manipulation

         10. There is angiographic evidence of a patent Common an Deep Femoral Artery

        Exclusion Criteria:

          1. PTA is technically not possible (not feasible to access the lesion or a defect with
             the guidewire or balloon catheter)

          2. Presence of an aneurysm immediately adjacent to the site of stent implantation

          3. Stenosis distal to the site of stent implantation

          4. Lesions in or adjacent to essential collaterals(s)

          5. Lesions in locations subject to external compression

          6. Heavily calcified lesions resistant to PTA

          7. Patients with diffuse distal disease resulting in poor stent outflow

          8. Patients with a history of coagulation disorders

          9. Patients with aspirin allergy or bleeding complications and patients unable or
             unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to
             anticoagulant/antiplatelet therapy

         10. Fresh thrombus formation

         11. Patients with known hypersensitivity to the stent material(L605)

         12. The target lesion is either a modified TASC-II class B or D lesion with aortic or
             common femoral lesion involvement:

               -  Type B lesions

                  -Short (≤3 cm) stenosis of infrarenal aorta

               -  Type C lesions

                    -  Unilateral External Iliac Artery stenosis extending into the Common Femoral
                       Artery

                    -  Unilateral External Iliac Artery occlusion that involves the origins of the
                       Internal Iliac and/or Common Femoral Artery

                    -  Heavily calcified unilateral External Iliac Artery occlusion with or without
                       involvement of origins of the Internal Iliac and/or Common Femoral Artery

               -  Type D lesions

                    -  Infra-renal aortoiliac occlusion

                    -  Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring
                       treatment and not amenable to endograft placement or other lesions requiring
                       open aortic or iliac surgery

                    -  Diffuse multiple stenoses involving the unilateral Common Iliac, External
                       Iliac and Common Femoral Artery

                    -  Unilateral occlusions of both Common Iliac and External Iliac Artery

                    -  Diffuse disease involving the aorta and both iliac arteries requiring
                       treatment

                    -  Bilateral occlusions of the External Iliac Artery

         13. Previously implanted stent(s) at the same lesion site

         14. Reference segment diameter is not suitable for the available stent design

         15. Untreatable lesion located at the distal outflow arteries

         16. Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation
             therapy) as part of the index procedure

         17. Patients refusing treatment

         18. Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are
             contraindicated

         19. Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion
             site

         20. Perforation at the angioplasty site evidenced by extravasation of contrast medium

         21. Patients with a history of prior life-threatening contrast medium reaction

         22. Patients with uncorrected bleeding disorders

         23. Female patient with child bearing potential not taking adequate contraceptives or
             currently breastfeeding

         24. Life expectancy of less than twelve months

         25. Any planned surgical intervention/procedure within 30 days of the study procedure

         26. Any patient considered to be hemodynamically unstable at onset of procedure

         27. Patient is currently participating in another investigational drug or device study
             that has not completed the entire follow up period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koen Deloose, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Flanders Medical Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OLV Hospital</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imelda Hospital Bonheiden</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Blasius</name>
      <address>
        <city>Dendermonde</city>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilig Hart Hospital</name>
      <address>
        <city>Tienen</city>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

